盘点:急性淋巴细胞白血病近期重要研究进展汇总

2018-04-12 MedSci MedSci原创

急性淋巴细胞性白血病是最常见的儿童白血病。根据上海CDC(疾控中心)癌症传报系统报告,每10万个15岁以下儿童中,就有4.7人患有白血病。据此推算,全中国每年新增儿童白血病患者约1.4万人,白血病已成为危害儿童健康的重大疾病之一。这里梅斯小编整理了近期关于急性淋巴细胞性白血病的重要研究进展,与大家一同分享。【1】抑制FOXO1活性或许可成为B细胞前体急性淋巴细胞白血病的新的有效疗法在B细胞分化

急性淋巴细胞性白血病是最常见的儿童白血病。根据上海CDC(疾控中心)癌症传报系统报告,每10万个15岁以下儿童中,就有4.7人患有白血病。据此推算,全中国每年新增儿童白血病患者约1.4万人,白血病已成为危害儿童健康的重大疾病之一。这里梅斯小编整理了近期关于急性淋巴细胞性白血病的重要研究进展,与大家一同分享。

【1】抑制FOXO1活性或许可成为B细胞前体急性淋巴细胞白血病的新的有效疗法

在B细胞分化早期,FOXO1转录因子在增殖和存活的调控过程中发挥重要作用。近期有研究人员发现严格调控FOXO1活性对维持B细胞前体急性淋巴细胞白血病(BCP-ALL)至关重要。遗传性或药理性失活BCP-ALL细胞系的FOXO1可产生与CCND3下调相关的强烈的抗白血病作用。而且,研究人员还发现CCND3的表达对BCP-ALL的存活至关重要,而过表达CCND3可保护BCP-ALL细胞系避免由FOXO1失活遇到的生长阻滞和凋亡。更重要的是,药物性抑制FOXO1,对几种原发性、患者来源的、儿童ALL移植瘤都具有抗白血病活性,可有效减少造血、淋巴和中枢神经系统器官中的白血病细胞,最终导致BCP-ALL的体内模型的临床前期无复发白血病状态的存活期延长。表明抑制FOXO1活性或许可有效治疗BCP-ALL。

【2】母亲糖尿病与子代儿童期急性淋巴细胞白血病风险

母亲患有糖尿病可能与子代儿童期急性淋巴细胞白血病(ALL)有关。近日,新的一项研究评估了产妇孕前或妊娠糖尿病与子代儿童期发生ALL风险之间的相关性。纳入了于1996年至2015年期间出生在丹麦的所有单胎儿童(n=1187482)。发现产妇妊娠前糖尿病子代儿童期发生ALL调整后的风险比为2.91,而妊娠期糖尿病产妇子代儿童期发生ALL调整后的风险比为1.75。父亲患糖尿病并没有改变子代儿童期发生ALL的风险,研究人员发现子代儿童期发生ALL与母亲后期发生糖尿病的风险之间没有关联。由此可见,尽管糖尿病妇女子代发生ALL的绝对风险很低,该研究结果表明糖尿病宫内环境的特点促进了ALL的发生发展。

【3】Kymriahc治疗儿童和青年复发或难治性B细胞急性淋巴细胞白血病

在先前开展的单中心1-2a期临床研究中,抗CD 19嵌合抗原受体T细胞疗法对儿童和青年复发性或难治性B细胞急性淋巴细胞白血病(ALL)具有很高的完全缓解率,但存在可逆的毒性作用。近日研究人员公布了儿童和青年CD 19+复发或难治性B细胞ALL患者II期临床研究的组织学研究结果。75名患者接受Kymriahc单次治疗并参与有效性评估。总体上,治疗3个月后的缓解率为81%,所有应答患者微小疾病残留阴性。6个月的无事件生存以及总生存率分别为73%和90%,12个月为50%和76%。中位缓解时间未达到。Kymriahc治疗的持续效应可长达20个月。73%的患者出现3-4级不良事件。77%的患者发生细胞因子释放综合征,其中48%的患者接受了托珠单抗治疗;40%的患者发生神经功能事件,所有患者均接受维持治疗,无脑水肿报道。

【4】博纳吐单抗用于最小残留病灶阳性的B前体急性淋巴细胞白血病患者的效果和安全性

约30-50%的急性淋巴细胞白血病(ALL)在多重治疗获得血液学完全缓解后可通过逆转录-聚合酶链反应或流式细胞术来检测最小残留病(MRD)。MRD是ALL复发最强的预示指标。一项开放性、单臂研究纳入了获得血液学完全缓解的、且残存MRD((≥10-3)的B前体ALL患者,予以博纳吐单抗(blinatumomab)15ug/m2/日 静脉用药,持续4个疗程。患者可在第一个疗程后任何时间接受同种异体造血干细胞移植。共有160位患者接受博纳吐单抗治疗,113位可评估的患者中有88位(78%)获得完全性MRD反应。在血液学缓解的110位费城染色体阴性的ALL患者亚群中,18个月时无复发存活期(RFS)估计值是53%。中位存活期是36.5个月。与MRD无反应者相比,完全性MRD反应者无复发存活期和总体存活期(OS)均更长。不良反应与既往对博纳吐单抗的研究中出现的一样。分别有12位(10%)和3位(3%)患者出现3或4级的神经性副作用。在第1疗程,4位(3%)患者出现细胞因子释放综合征(1例2级、2例3级)。

【5】儿童期感染与儿童急性淋巴细胞白血病风险


近日,一项新的研究旨在明确儿童感染是否与儿童急性淋巴细胞白血病(ALL)的发生有关。纳入了所有评估0岁至19岁的ALL儿童与无ALL儿童诊断前感染情况的研究。对来自于3项研究的12496名ALL儿童和2356288名无ALL儿童进行主要分析,研究人员发现任何感染与儿童ALL无关。在实验室确诊的感染研究中,感染导致ALL发生几率增加了2.4倍。感染的频率、严重程度和感染时机与ALL无关。由此可见,该研究提出的感染病因假设既不支持也不反驳感染与ALL之间的相关性。亚组效应的定量差异需要进一步研究,未来的研究将需要处理好感染暴露测量方面的挑战。


【6】在Ph样急性淋巴细胞白血病中发现一新的与酪氨酸激酶抑制剂耐药性直接相关的PDGFRB突变

费城染色体样急性淋巴细胞白血病(Ph-样ALL)大约占所有儿童ALL病例的10-15%,其中很多人对酪氨酸激酶抑制剂(TKIs)反应非常敏感,如伊马替尼对PDGFRB重排的ALL。但是,现在有很多病例出现对TKIs的药物耐药性,而且机制不明。新的研究中,研究人员发现了一种新的PDGFRB融合基因,命名为AGGF1-PDGFRB,并在功能上表征了其在体外的致癌潜力。在治疗过程中,对纵向采集的样本进行进一步基因组学分析发现,PDGFRBC843G突变的出现,直接导致了对所有世代的ABL TKIs的耐药,包括伊马替尼、达沙替尼、尼洛替尼和帕纳替尼。PDGFRB突变型白血病细胞对多种靶向激酶抑制剂CHZ868高度敏感,提示或许可作为对ABL TKIs耐药的患者的潜在治疗选择。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1997891, encodeId=3654199e891d4, content=<a href='/topic/show?id=75ff66001cd' target=_blank style='color:#2F92EE;'>#淋巴细胞白血病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66001, encryptionId=75ff66001cd, topicName=淋巴细胞白血病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1be8234, createdName=sunyl07, createdTime=Tue Sep 04 14:29:00 CST 2018, time=2018-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=306797, encodeId=7f99306e97fe, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJpBl6xwMmnsKibwxcAIltOH3nnCEQbNE6TDbYtCKe8hYI0oJrbduNqnJraM1PyyjPKU1suAzicYPaA/132, createdBy=eeaf2031798, createdName=海之蓝, createdTime=Wed Apr 18 05:47:56 CST 2018, time=2018-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302156, encodeId=0b001302156d0, content=<a href='/topic/show?id=82a6659902c' target=_blank style='color:#2F92EE;'>#淋巴细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65990, encryptionId=82a6659902c, topicName=淋巴细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e34303, createdName=wetgdt, createdTime=Sat Apr 14 14:29:00 CST 2018, time=2018-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1380979, encodeId=a04c13809e988, content=<a href='/topic/show?id=9281e34519b' target=_blank style='color:#2F92EE;'>#研究进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73451, encryptionId=9281e34519b, topicName=研究进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f13d475, createdName=mashirong, createdTime=Sat Apr 14 14:29:00 CST 2018, time=2018-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=305221, encodeId=031c3052216b, content=学习了很有用, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib3IzoRn621JdKCFUI4XvNELcibocrAVU6aUzEVDSaf3rYH08PUYUiagGqxAEhj8g9WqqNvD1CupIpCrmnR2OrqHZh/0, createdBy=7f181365728, createdName=飛歌, createdTime=Fri Apr 13 00:14:33 CST 2018, time=2018-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=305207, encodeId=0e1e30520eae, content=谢谢分享学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Thu Apr 12 23:31:22 CST 2018, time=2018-04-12, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1997891, encodeId=3654199e891d4, content=<a href='/topic/show?id=75ff66001cd' target=_blank style='color:#2F92EE;'>#淋巴细胞白血病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66001, encryptionId=75ff66001cd, topicName=淋巴细胞白血病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1be8234, createdName=sunyl07, createdTime=Tue Sep 04 14:29:00 CST 2018, time=2018-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=306797, encodeId=7f99306e97fe, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJpBl6xwMmnsKibwxcAIltOH3nnCEQbNE6TDbYtCKe8hYI0oJrbduNqnJraM1PyyjPKU1suAzicYPaA/132, createdBy=eeaf2031798, createdName=海之蓝, createdTime=Wed Apr 18 05:47:56 CST 2018, time=2018-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302156, encodeId=0b001302156d0, content=<a href='/topic/show?id=82a6659902c' target=_blank style='color:#2F92EE;'>#淋巴细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65990, encryptionId=82a6659902c, topicName=淋巴细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e34303, createdName=wetgdt, createdTime=Sat Apr 14 14:29:00 CST 2018, time=2018-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1380979, encodeId=a04c13809e988, content=<a href='/topic/show?id=9281e34519b' target=_blank style='color:#2F92EE;'>#研究进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73451, encryptionId=9281e34519b, topicName=研究进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f13d475, createdName=mashirong, createdTime=Sat Apr 14 14:29:00 CST 2018, time=2018-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=305221, encodeId=031c3052216b, content=学习了很有用, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib3IzoRn621JdKCFUI4XvNELcibocrAVU6aUzEVDSaf3rYH08PUYUiagGqxAEhj8g9WqqNvD1CupIpCrmnR2OrqHZh/0, createdBy=7f181365728, createdName=飛歌, createdTime=Fri Apr 13 00:14:33 CST 2018, time=2018-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=305207, encodeId=0e1e30520eae, content=谢谢分享学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Thu Apr 12 23:31:22 CST 2018, time=2018-04-12, status=1, ipAttribution=)]
    2018-04-18 海之蓝

    学习

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1997891, encodeId=3654199e891d4, content=<a href='/topic/show?id=75ff66001cd' target=_blank style='color:#2F92EE;'>#淋巴细胞白血病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66001, encryptionId=75ff66001cd, topicName=淋巴细胞白血病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1be8234, createdName=sunyl07, createdTime=Tue Sep 04 14:29:00 CST 2018, time=2018-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=306797, encodeId=7f99306e97fe, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJpBl6xwMmnsKibwxcAIltOH3nnCEQbNE6TDbYtCKe8hYI0oJrbduNqnJraM1PyyjPKU1suAzicYPaA/132, createdBy=eeaf2031798, createdName=海之蓝, createdTime=Wed Apr 18 05:47:56 CST 2018, time=2018-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302156, encodeId=0b001302156d0, content=<a href='/topic/show?id=82a6659902c' target=_blank style='color:#2F92EE;'>#淋巴细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65990, encryptionId=82a6659902c, topicName=淋巴细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e34303, createdName=wetgdt, createdTime=Sat Apr 14 14:29:00 CST 2018, time=2018-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1380979, encodeId=a04c13809e988, content=<a href='/topic/show?id=9281e34519b' target=_blank style='color:#2F92EE;'>#研究进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73451, encryptionId=9281e34519b, topicName=研究进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f13d475, createdName=mashirong, createdTime=Sat Apr 14 14:29:00 CST 2018, time=2018-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=305221, encodeId=031c3052216b, content=学习了很有用, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib3IzoRn621JdKCFUI4XvNELcibocrAVU6aUzEVDSaf3rYH08PUYUiagGqxAEhj8g9WqqNvD1CupIpCrmnR2OrqHZh/0, createdBy=7f181365728, createdName=飛歌, createdTime=Fri Apr 13 00:14:33 CST 2018, time=2018-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=305207, encodeId=0e1e30520eae, content=谢谢分享学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Thu Apr 12 23:31:22 CST 2018, time=2018-04-12, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1997891, encodeId=3654199e891d4, content=<a href='/topic/show?id=75ff66001cd' target=_blank style='color:#2F92EE;'>#淋巴细胞白血病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66001, encryptionId=75ff66001cd, topicName=淋巴细胞白血病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1be8234, createdName=sunyl07, createdTime=Tue Sep 04 14:29:00 CST 2018, time=2018-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=306797, encodeId=7f99306e97fe, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJpBl6xwMmnsKibwxcAIltOH3nnCEQbNE6TDbYtCKe8hYI0oJrbduNqnJraM1PyyjPKU1suAzicYPaA/132, createdBy=eeaf2031798, createdName=海之蓝, createdTime=Wed Apr 18 05:47:56 CST 2018, time=2018-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302156, encodeId=0b001302156d0, content=<a href='/topic/show?id=82a6659902c' target=_blank style='color:#2F92EE;'>#淋巴细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65990, encryptionId=82a6659902c, topicName=淋巴细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e34303, createdName=wetgdt, createdTime=Sat Apr 14 14:29:00 CST 2018, time=2018-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1380979, encodeId=a04c13809e988, content=<a href='/topic/show?id=9281e34519b' target=_blank style='color:#2F92EE;'>#研究进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73451, encryptionId=9281e34519b, topicName=研究进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f13d475, createdName=mashirong, createdTime=Sat Apr 14 14:29:00 CST 2018, time=2018-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=305221, encodeId=031c3052216b, content=学习了很有用, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib3IzoRn621JdKCFUI4XvNELcibocrAVU6aUzEVDSaf3rYH08PUYUiagGqxAEhj8g9WqqNvD1CupIpCrmnR2OrqHZh/0, createdBy=7f181365728, createdName=飛歌, createdTime=Fri Apr 13 00:14:33 CST 2018, time=2018-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=305207, encodeId=0e1e30520eae, content=谢谢分享学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Thu Apr 12 23:31:22 CST 2018, time=2018-04-12, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1997891, encodeId=3654199e891d4, content=<a href='/topic/show?id=75ff66001cd' target=_blank style='color:#2F92EE;'>#淋巴细胞白血病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66001, encryptionId=75ff66001cd, topicName=淋巴细胞白血病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1be8234, createdName=sunyl07, createdTime=Tue Sep 04 14:29:00 CST 2018, time=2018-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=306797, encodeId=7f99306e97fe, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJpBl6xwMmnsKibwxcAIltOH3nnCEQbNE6TDbYtCKe8hYI0oJrbduNqnJraM1PyyjPKU1suAzicYPaA/132, createdBy=eeaf2031798, createdName=海之蓝, createdTime=Wed Apr 18 05:47:56 CST 2018, time=2018-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302156, encodeId=0b001302156d0, content=<a href='/topic/show?id=82a6659902c' target=_blank style='color:#2F92EE;'>#淋巴细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65990, encryptionId=82a6659902c, topicName=淋巴细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e34303, createdName=wetgdt, createdTime=Sat Apr 14 14:29:00 CST 2018, time=2018-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1380979, encodeId=a04c13809e988, content=<a href='/topic/show?id=9281e34519b' target=_blank style='color:#2F92EE;'>#研究进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73451, encryptionId=9281e34519b, topicName=研究进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f13d475, createdName=mashirong, createdTime=Sat Apr 14 14:29:00 CST 2018, time=2018-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=305221, encodeId=031c3052216b, content=学习了很有用, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib3IzoRn621JdKCFUI4XvNELcibocrAVU6aUzEVDSaf3rYH08PUYUiagGqxAEhj8g9WqqNvD1CupIpCrmnR2OrqHZh/0, createdBy=7f181365728, createdName=飛歌, createdTime=Fri Apr 13 00:14:33 CST 2018, time=2018-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=305207, encodeId=0e1e30520eae, content=谢谢分享学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Thu Apr 12 23:31:22 CST 2018, time=2018-04-12, status=1, ipAttribution=)]
    2018-04-13 飛歌

    学习了很有用

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1997891, encodeId=3654199e891d4, content=<a href='/topic/show?id=75ff66001cd' target=_blank style='color:#2F92EE;'>#淋巴细胞白血病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66001, encryptionId=75ff66001cd, topicName=淋巴细胞白血病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1be8234, createdName=sunyl07, createdTime=Tue Sep 04 14:29:00 CST 2018, time=2018-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=306797, encodeId=7f99306e97fe, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJpBl6xwMmnsKibwxcAIltOH3nnCEQbNE6TDbYtCKe8hYI0oJrbduNqnJraM1PyyjPKU1suAzicYPaA/132, createdBy=eeaf2031798, createdName=海之蓝, createdTime=Wed Apr 18 05:47:56 CST 2018, time=2018-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302156, encodeId=0b001302156d0, content=<a href='/topic/show?id=82a6659902c' target=_blank style='color:#2F92EE;'>#淋巴细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65990, encryptionId=82a6659902c, topicName=淋巴细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e34303, createdName=wetgdt, createdTime=Sat Apr 14 14:29:00 CST 2018, time=2018-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1380979, encodeId=a04c13809e988, content=<a href='/topic/show?id=9281e34519b' target=_blank style='color:#2F92EE;'>#研究进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73451, encryptionId=9281e34519b, topicName=研究进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f13d475, createdName=mashirong, createdTime=Sat Apr 14 14:29:00 CST 2018, time=2018-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=305221, encodeId=031c3052216b, content=学习了很有用, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib3IzoRn621JdKCFUI4XvNELcibocrAVU6aUzEVDSaf3rYH08PUYUiagGqxAEhj8g9WqqNvD1CupIpCrmnR2OrqHZh/0, createdBy=7f181365728, createdName=飛歌, createdTime=Fri Apr 13 00:14:33 CST 2018, time=2018-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=305207, encodeId=0e1e30520eae, content=谢谢分享学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Thu Apr 12 23:31:22 CST 2018, time=2018-04-12, status=1, ipAttribution=)]
    2018-04-12 清风拂面

    谢谢分享学习

    0